At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
cixutumumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating cixutumumab, computed tomography, and 1 other intervention for Adult Primary Hepatocellular Carcinoma and 3 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionFeb 2011
TodayJul 2026
First PostedMar 20, 2008
Enrollment StartMar 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.3 years ago
Interventions
cixutumumabbiological
Given IV
computed tomographyprocedure
Undergo contrast-enhanced computed tomography
contrast-enhanced magnetic resonance imagingprocedure
Undergo contrast-enhanced magnetic resonance imaging